Vincent Lin, Chairman of TCI, stated yesterday (21st) that the company has successfully entered the top three global pharmaceutical companies, the top three U.S. direct selling companies, and major international internet giants, marking its transformation into a truly global enterprise operating simultaneously across the U.S., Europe, and Asia-Pacific. To support this expansion, TCI is advancing its “asset-light strategy” and is currently evaluating the establishment of a production base in Spain.
Regarding this year’s operations, Lin noted that delays in installing new liquid pouch equipment and the impact of tariffs caused revenues in the first seven months to dip slightly. However, with customer orders resuming in August and production capacity gradually ramping up, performance in the second half of the year is expected to strengthen and turn full-year revenue growth back into positive territory.
Lin emphasized that the company’s customer mix has completely shifted. Previously focused on major Chinese brands and micro-distributors, TCI now serves some of the world’s leading enterprises, including the top three global pharmaceutical firms, the top three U.S. direct selling companies, and international internet giants. Revenue from North America and Asia-Pacific has grown rapidly, while China’s contribution has dropped from 73% to just 24% in Q2. In contrast, the U.S. share surged from 8% to 30%, Asia-Pacific from 15% to 32%, and Europe from 4% to 14%.
Today, TCI’s products are sold in 67 markets worldwide, serving over 1,400 brand customers, including more than 15 multinational companies with annual revenue exceeding US$1 billion. Lin explained that penetrating these large corporations is extremely challenging and requires direct engagement with CEOs and COOs to convince them why sourcing from Taiwan is preferable over local suppliers in the U.S., UK, or Europe. Overall, TCI has successfully transformed from a company focused on Chinese-speaking markets into a global enterprise with the U.S. and Asia-Pacific as its core, while advancing steadily in Europe—demonstrating strong international competitiveness in R&D, manufacturing, and business development.
In response to global currency fluctuations and geopolitical risks, TCI launched “TCI Biotech 2.0,” shifting its manufacturing model from centralized to distributed. Through its “City Factory” strategy, the company is building facilities near key markets to quickly respond to demand. The plan calls for at least six asset-light manufacturing bases and 10 multinational offices across Asia, the Americas, and Europe.
The India factory is already operational, using relocated equipment from Taiwan to serve local multinational clients first. TCI is also evaluating a site in Barcelona, Spain—chosen not only for cost reasons but also because it hosts the world’s largest health supplement trade fair, which attracts more than 40,000 senior executives and decision-makers each year. If confirmed, TCI plans to purchase an existing plant and invest in cleanrooms and equipment, with operations expected within 18 months.
To reflect its global expansion, TCI recently introduced a new brand identity. The updated logo integrates “tci” with the Chinese name “大江,” with a red spark symbolizing the “spark of creativity lighting up the future,” embodying the spirit of innovation, youthfulness, and globalization in the 2.0 era.
Meanwhile, TCI’s proprietary “Zero O2” oxygen-free manufacturing technology is driving explosive demand by extending the activity and shelf life of nutritional supplements. Lin revealed that current orders for liquid pouches alone total 95 million units, but existing capacity can only fulfill around 30 million. The company is accelerating expansion, with future new production lines to be built directly in overseas markets.
TCI’s product strategy follows the principle of “launching one star product every three years.” In addition to the expanding market applications of its GLP-1 Formul and growing sales in Europe and the U.S., the company’s next major star product—set for 2026—will target the field of blood glucose management, specifically proanthocyanidins from peanut skins, which can help reduce postprandial blood sugar fluctuations.
For the first half of the year, TCI posted net profit after tax of NT$442 million, with EPS of NT$3.39. Revenue from January to July was NT$3.968 billion, down 3.46% year-on-year, mainly due to delays in installing the new liquid pouch equipment, which was only completed in May, with mass production beginning in June. Tariff concerns also led some customers to hold back orders. Since August, however, most customers have resumed purchasing, shipments are steadily recovering, and new production capacity is gradually being released. Lin expressed confidence that stronger second-half growth will drive full-year revenue back to positive growth.
Resource: 大江輕資產布局將前進西班牙，新設備到位＋關稅影響降，H2業績拚轉強
